The primary mechanism through which ST7 inhibitors operate involves modulating chromatin structure and DNA accessibility, thereby affecting the regulatory functions of ST7 in gene expression. This modulation of chromatin structure, achieved by influencing enzymes responsible for chromatin remodeling, can change the transcriptional activity of genes under the regulatory umbrella of ST7. By altering the chromatin landscape, these inhibitors can influence the transcriptional dynamics and affect the pathways where ST7 exerts its tumor suppressive functions. The influence on chromatin structure can lead to changes in gene expression patterns, impacting the regulatory roles played by ST7.
These inhibitors target a variety of enzymes and processes that are integral to chromatin remodeling and gene expression regulation. By affecting histone acetylation and methylation, these compounds can alter the transcriptional landscape, impacting ST7's role in tumor suppression. The changes in histone modification patterns, brought about by these inhibitors, can lead to alterations in the accessibility of DNA to transcription factors and other regulatory proteins, thus influencing the gene expression profiles relevant to ST7's function. Additionally, some of these compounds bind directly to DNA, impacting the transcriptional processes and influencing the regulatory roles of ST7. The overarching effect of these inhibitors is to modulate the cellular environment in which ST7 operates, thereby influencing its ability to regulate gene expression and maintain cellular homeostasis. It's important to note that the specific effects of these inhibitors on ST7 are subject to research and are not confined to a narrow pathway. The complex nature of tumor suppressor gene regulation and the broad effects of these inhibitors on chromatin and gene expression make their specific impact on ST7 a subject of ongoing scientific inquiry. These compounds, by targeting processes fundamental to gene expression and chromatin structure, present a method to influence the regulatory environment of ST7, thereby affecting its role in cellular processes.
Items 1 to 10 of 18 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Histone deacetylase inhibitor; could possibly inhibit ST7 by altering chromatin structure and affecting gene expression related to its tumor suppressive functions. | ||||||
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $30.00 $87.00 $132.00 $434.00 | 13 | |
Simvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. This could possibly inhibit ST7 function by leading to upregulation of LDLR expression. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
DNA methyltransferase inhibitor; could possibly inhibit ST7 by impacting DNA methylation patterns, influencing gene expression profiles associated with its activity. | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $252.00 $495.00 | 9 | |
Atorvastatin acts similarly to Simvastatin by inhibiting HMG-CoA reductase. This could possibly inhibit ST7 function by influencing LDLR expression. | ||||||
Lovastatin | 75330-75-5 | sc-200850 sc-200850A sc-200850B | 5 mg 25 mg 100 mg | $28.00 $88.00 $332.00 | 12 | |
Lovastatin is another statin that can inhibit HMG-CoA reductase. This could possibly inhibit ST7 function by influencing LDLR expression. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $142.00 | 8 | |
Rosuvastatin, a statin, can also inhibit HMG-CoA reductase. This could possibly inhibit ST7 function by affecting LDLR expression. | ||||||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $68.00 $159.00 $772.00 | 2 | |
Pravastatin is a statin that can inhibit HMG-CoA reductase. This could possibly inhibit ST7 function by influencing LDLR expression. | ||||||
RGFP966 | 1357389-11-7 | sc-507300 | 5 mg | $115.00 | ||
Selective HDAC3 inhibitor; could possibly inhibit ST7 by influencing chromatin structure, affecting related gene expression. | ||||||
Fluvastatin | 93957-54-1 | sc-279169 | 50 mg | $250.00 | ||
Fluvastatin, another statin, can inhibit HMG-CoA reductase. This could possibly inhibit ST7 function by affecting LDLR expression. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Antitumor antibiotic; binds to DNA and could possibly inhibit ST7 by interfering with transcriptional processes related to its tumor suppressive role. |